|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
1R43CA210817-01A1
|
$152,589
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of tunneling nanotubes as a novel mode of tumor cell-macrophage communication
|
5F99CA212451-02
|
$44,044
|
HANNA, SAMER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
2R44CA183362-02A1
|
$822,075
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
P53 inactivation on MDSC development and tumor progression
|
5R01CA169133-05
|
$315,400
|
CUI, YAN
|
AUGUSTA UNIVERSITY
|
|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-02
|
$33,744
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-08
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-04
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-04
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
7R01CA132115-08
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Risk Prediction for ER Negative Breast Cancer Recurrence
|
5R01CA172511-05
|
$593,132
|
BONDY, MELISSA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis
|
5R01CA168717-05
|
$323,700
|
ELEFTERIOU, FLORENT
|
BAYLOR COLLEGE OF MEDICINE
|
|
MECHANISMS OF AR-ER COLLABORATION IN HORMONE RESISTANCE AND METASTASIS OF BREAST CANCER
|
1R01CA207270-01A1
|
$362,569
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-19
|
$320,963
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenomic reprogramming driven by mutant ER? in metastatic breast cancer
|
5F31CA210385-02
|
$43,993
|
GATES, LEAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Germ Cell Gene TDRD1 As A Novel Prostate Cancer Biomarker
|
1R01CA211861-01A1
|
$362,569
|
HE, BIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
1R01CA215452-01
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-01S1
|
$14,309
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
5R01CA190467-03
|
$362,569
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-04
|
$336,565
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-04
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
1R03CA215940-01
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Osteoclast-independent mechanisms of early-stage bone colonization of breast canc
|
5R01CA183878-04
|
$324,738
|
ZHANG, XIANG
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-02
|
$352,363
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER
|
4R00CA201075-03
|
$249,000
|
FENG, MINGYE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Control of tumor growth and metastasis by the cytokine TSLP
|
3R01CA182783-04S1
|
$119,849
|
ZIEGLER, STEVEN
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-03
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-04
|
$355,719
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Investigation and functional characterization of new drivers of mesenchymal tumorigenesis.
|
5K99CA212200-02
|
$102,130
|
GUARNERIO, JLENIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
|
4R44CA203068-02
|
$988,207
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
7U24CA184407-05
|
$586,963
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Impaired Glycosylation of Vascular Endothelial Growth Factor Receptor 2 in Tumor Angiogenesis
|
3F32CA196157-02S1
|
$316
|
CHANDLER, KEVIN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|